Diabetes & metabolism最新文献

{"title":"Glucagon-like peptide-1 receptor agonists and the risk of nonarteritic anterior ischemic optic neuropathy: Evidence from a global real-world cohort","authors":"Jun-Wei Chen ,&nbsp;Frederick Tzu-En Yu ,&nbsp;Hsin-An Chen ,&nbsp;Tzu-Fu Huang ,&nbsp;Harn-Shen Chen ,&nbsp;Tzu-En Wu","doi":"10.1016/j.diabet.2026.101740","DOIUrl":"10.1016/j.diabet.2026.101740","url":null,"abstract":"<div><h3>Aims</h3><div>To evaluate whether GLP-1 RA therapy is associated with an increased risk of NAION in a large, diverse real-world population.</div></div><div><h3>Methods</h3><div>This retrospective cohort study utilized the TriNetX U.S. Collaborative Network from 2015 to 2024. Adults (≥18 years) with type 2 diabetes mellitus (T2DM) were identified and grouped as GLP-1 RA users versus other antidiabetic users and GLP-1 RA users versus sodium-glucose cotransporter-2 inhibitors (SGLT-2 i) users. Patients with preexisting optic neuropathy or severe ocular disease were excluded. Propensity score matching (1:1) was applied to balance baseline characteristics. The primary outcome was incident NAION, defined by ICD-10 codes. Cox proportional hazards models and Kaplan–Meier analyses were used to estimate hazard ratios (HRs) and cumulative probabilities.</div></div><div><h3>Results</h3><div>After matching, 799 036 GLP-1 RA users were compared with 799 036 other antidiabetic users, and 429 985 GLP-1 RA users were compared with 429 985 SGLT-2i users. Over 9 years, GLP-1 RA users showed higher cumulative NAION incidence vs other agents (0.21% vs 0.17%; HR 1.38; 95% CI, 1.23–1.55) and vs SGLT-2i users (0.20% vs 0.20%; HR 1.30; 95% CI, 1.11–1.52). Kaplan–Meier curves demonstrated consistent early separation favoring higher risk among GLP-1 RA users. Sensitivity analyses yielded similar patterns.</div></div><div><h3>Conclusions</h3><div>GLP-1 RA therapy was associated with a modest but statistically significant increased risk of NAION. While the absolute risk remains low, clinicians should consider ophthalmic risk assessment—particularly in patients with anatomical susceptibility or vascular risk factors—as GLP-1 RA use expands for diabetes and obesity management. Further mechanistic and prospective research is warranted.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 2","pages":"Article 101740"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146195584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overview of the major clinical trials investigating stem cells–based therapies for diabetes","authors":"Tzu-Min Lin ,&nbsp;Tzu-Ching Lin ,&nbsp;Cheng-Han Lin ,&nbsp;Chih-Sheng Lin","doi":"10.1016/j.diabet.2026.101738","DOIUrl":"10.1016/j.diabet.2026.101738","url":null,"abstract":"<div><div>Stem cell–based therapies are a leading frontier in diabetes treatment, aiming to restore insulin-producing β-cell function beyond symptomatic management. Clinical progress has evolved from donor islet transplantation, such as the Edmonton Protocol, to pluripotent stem cell–derived β-cell replacement. Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) can differentiate into insulin-producing cells, while mesenchymal stem cells (MSCs) provide immunomodulatory and metabolic support. Landmark trials by ViaCyte, Vertex, and Sernova tested ESCs- and iPSCs-derived progenitors with encapsulation devices and bioengineered niches, yielding insights into safety, differentiation, and immune responses. Vertex’s VX-880 program achieved insulin independence, and a 2024 Cell study reported the first functional cure of type 1 diabetes using chemical induced iPSCs (CiPSCs)-derived islets. Encapsulation technologies dominate trials, aiming to shield transplanted cells from rejection without systemic immunosuppression, though fibrosis and vascularization remain obstacles. MSCs therapies across Phase 1–3 trials improved glycemic control and β-cell preservation, underscoring their complementary role. Despite promising outcomes, no clinical stem cell–derived therapy is yet routine, with tumorigenicity, immune rejection, and scalability as key challenges. Future directions focus on gene-edited immune-evasive cells, advanced biomaterials, scalable bioreactors, and harmonized regulation to achieve durable insulin independence and global accessibility.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 2","pages":"Article 101738"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146121620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of dyslipidemia in adults. A consensus statement from the French Society of Endocrinology (SFE), the French-speaking Diabetes Society (SFD), the New French-speaking Atherosclerosis Society (NSFA) and the French Society of Cardiology (SFC)","authors":"Benjamin Bouillet ,&nbsp;Romain Boulestreau ,&nbsp;Victor Aboyans ,&nbsp;Sophie Béliard ,&nbsp;Franck Boccara ,&nbsp;Bertrand Cariou ,&nbsp;Sybil Charrière ,&nbsp;Philippe Moulin ,&nbsp;Bruno Vergès ,&nbsp;Rene Valero ,&nbsp;Antonio Gallo","doi":"10.1016/j.diabet.2026.101725","DOIUrl":"10.1016/j.diabet.2026.101725","url":null,"abstract":"","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 2","pages":"Article 101725"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146133892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A clinical prediction model for beta cell monogenetic diabetes in Chinese patients with early-onset type 2 diabetes","authors":"Siyu Sun ,&nbsp;Siqian Gong ,&nbsp;Tianhao Ba ,&nbsp;Meng Li ,&nbsp;Wei Liu ,&nbsp;Rui Zhang ,&nbsp;Yumin Ma ,&nbsp;Fang Wang ,&nbsp;Xiaoling Cai ,&nbsp;Yingying Luo ,&nbsp;Simin Zhang ,&nbsp;Lingli Zhou ,&nbsp;Yu Zhu ,&nbsp;Xiuying Zhang ,&nbsp;Jing Chen ,&nbsp;Ling Chen ,&nbsp;Jing Wu ,&nbsp;Leili Gao ,&nbsp;Xianghai Zhou ,&nbsp;Liyong Zhong ,&nbsp;Linong Ji","doi":"10.1016/j.diabet.2026.101729","DOIUrl":"10.1016/j.diabet.2026.101729","url":null,"abstract":"<div><h3>Aim</h3><div>Monogenic diabetes is a group of disorders arising from single gene mutations with a clear pathophysiology, most of which present with impaired beta cell function rather than insulin resistance. This study aims to evaluate the ability of TyG index and polygenetic risk score (PRS) to identify multi-type beta cell monogenetic diabetes (beta-cell-MgD) in Chinese early-onset type 2 diabetes (EOD) population.</div></div><div><h3>Methods</h3><div>A prediction model for beta-cell-MgD was established by logistic regression analysis in Cohort 1 (92 beta-cell-MgD, 512 EOD). Model performance was evaluated by receiver operating characteristic curves (ROC) and validated in an independent case-control sample (Cohort 2, 35 beta-cell-MgD, 50 EOD) and a newly diagnosed drug-naive EOD cohort (Cohort 3, 7 beta-cell-MgD, 176 EOD). PRS was constructed based on Genome-wide genotyping data from participants in Cohort 3. The ability of PRS to identify beta-cell-MgD was tested by ROC.</div></div><div><h3>Results</h3><div>The TyG-MgD score based on age at diagnosis, BMI and TyG presented a good performance to distinguish beta-cell-MgD (AUC=0.769), and achieving AUCs of 0.966 and 0.754 respectively in validation cohorts. At the optimal cutoff point -16.19, the model achieved a sensitivity of 66.3% and a specificity of 75.39%, allowing one case of beta-cell-MgD identified among every three patients. -16.85 could be used as the screening threshold prioritizing 80% sensitivity (with 59% specificity). Models combining TyG-MgD with East Asian PRS and beta-cell dysfunction-high proinsulin partitioned polygenetic score showed AUCs of 0.842 and 0.834 respectively for indentifying beta-cell-MgD.</div></div><div><h3>Conclusion</h3><div>We developed a clinical prediction model as a simple screening tool for multi-type beta-cell-MgD, identifying who are most likely to benefit from next genetic sequencing in Chinese population. PRS might be helpful for further screening of MgD.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 2","pages":"Article 101729"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145994568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epicardial adipose tissue measurement is an interesting biomarker for cardiovascular health in a case control study of patients with familial partial type 2 lipodystrophy","authors":"Mathilde Simonson ,&nbsp;Patricia Ancel ,&nbsp;Romain Mortier ,&nbsp;Mohamed Lamine Mariko ,&nbsp;Bénédicte Fontaine ,&nbsp;Julie Koue-Chon-Lim ,&nbsp;Jules Martel ,&nbsp;Estelle Nobécourt ,&nbsp;Bénédicte Gaborit","doi":"10.1016/j.diabet.2025.101719","DOIUrl":"10.1016/j.diabet.2025.101719","url":null,"abstract":"<div><h3>Aim</h3><div>Clinical cardiovascular risk scoring and Coronary artery calcification evaluation are lacking in Type 2 Familial Partial Lipodystrophy patients who present higher cardiovascular events and risk factors. The epicardial adipose tissue volume - a visceral adipose tissue which is accumulated during lipodystrophy - is higher in type 2 diabetic patients with coronary artery disease. In this case control study, we assessed epicardial adipose tissue volume as a new marker of interest in these patients.</div></div><div><h3>Methods</h3><div>Patients with type 2 Familial Partial Lipodystrophy or control patients, in primary prevention for cardiovascular events, were followed up at the University Hospital of La Réunion. Type 2 Familial Partial Lipodystrophy patients undergoing both coronary artery calcification and clinical cardiovascular risk scoring were retrospectively included and paired with control patients for age, sex and body mass index (NCT07090629). The epicardial adipose tissue volume was measured for each of the 126 subjects, with a semi-automated technique using deep learning and AI. Results: Type 2 Familial Partial Lipodystrophy patients displayed significantly higher adipose tissue volume (77 ± 39 cm³) than control subjects at high cardiovascular risk (60 ± 30 cm³; <em>P</em> = 0.010).</div></div><div><h3>Conclusions</h3><div>we show for the first time patients with Type 2 Familial Partial Lipodystrophy present higher values of epicardial adipose tissue volume, an interesting biomarker to add to coronary artery calcification and clinical scoring.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 1","pages":"Article 101719"},"PeriodicalIF":4.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145688836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pancreatic polypeptide in patients with type 1 diabetes and exocrine failure or chronic pancreatitis. The DIAPP study","authors":"Lea Dehghani ,&nbsp;Fideline Bonnet-Serrano ,&nbsp;Hendy Abdul ,&nbsp;Laure Alexandre-Heymann ,&nbsp;Jean Guibourdenche ,&nbsp;Etienne Larger","doi":"10.1016/j.diabet.2025.101712","DOIUrl":"10.1016/j.diabet.2025.101712","url":null,"abstract":"<div><h3>Introduction</h3><div><em>.</em> <strong>-</strong> Exocrine dysfunction can occur in type 1 diabetes (T1D). When exocrine function is impaired, it is unclear whether alterations also involve other endocrine cell types beyond beta cells. Pancreatic polypeptide (PP) is, besides insulin, the sole hormone that is specific to islets of Langerhans. The aim of the DIAPP study was to evaluate if PP secretion is also altered when T1D is complicated by exocrine failure.</div></div><div><h3>Materials and Methods</h3><div><em>. -</em> Seven patients with T1D and normal pancreatic function (T1DN), 9 patients with T1D and exocrine failure (T1DEF) were compared to 13 patients with type 3c diabetes; i. e. with chronic pancreatitis (CP). All of them had a mixed meal test (MMT), C-peptide and PP being determined before and at 60, 90 and 120 minutes.</div></div><div><h3>Results</h3><div><em>. –</em> The area under the curve of C-peptide during MMT (AUC_Cpep) was significantly greater in the CP group than in both T1D groups (<em>P</em> &lt; 0.0001 vs. the T1DEF group and <em>P</em> &lt; 0.001 vs. the T1D group) while the area under the curve of PP (AUC_PP) was significantly smaller in the CP group than in both T1D groups (<em>P</em> &lt; 0.01 vs. both groups). The AUC_PP / AUC_Cpep ratio was higher in the CP group than in both T1D groups (<em>P</em> &lt; 0.0001 vs. both groups).</div></div><div><h3>Conclusion</h3><div><em>. -</em> PP secretion was altered specifically in patients with CP, not in T1D, even when associated with pancreatic exocrine failure.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 1","pages":"Article 101712"},"PeriodicalIF":4.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145497968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Usefulness of continuous interstitial glucose in diabetic patient undergoing hemodialysis","authors":"Elise Berchoux ,&nbsp;Ilan Szwarc ,&nbsp;Jean-Baptiste Bonnet ,&nbsp;Joanna Pissarra ,&nbsp;Antoine Avignon ,&nbsp;Sébastien Jugant ,&nbsp;Moglie Le Quintrec ,&nbsp;Ariane Sultan","doi":"10.1016/j.diabet.2025.101720","DOIUrl":"10.1016/j.diabet.2025.101720","url":null,"abstract":"<div><h3>Backgroung</h3><div>In patients with type 2 diabetes (T2D) undergoing hemodialysis (HD), glycemic control is challenging, and glycated hemoglobin (HbA1c) is often unreliable due to altered red blood cell turnover, anemia, and treatments such as erythropoiesis-stimulating agents. Continuous glucose monitoring (CGM) provides additional metrics—such as time in range (TIR), time below range (TBR), and glycemic variability—that may better reflect glucose control in this population. This study aimed to assess the usefulness of 14-day CGM data compared to HbA1c in evaluating glycemic control in T2D patients on HD.</div></div><div><h3>Methods</h3><div>This is a prospective and multicenter study. Patients included were of &gt; 18 years, DM2, and hemodialysis patients. We assessed glycemic control of diabetic hemodialysis patient over 14 days with the CGM freestyle 1 comparing to HbA1c.</div></div><div><h3>Results</h3><div>Forty-one patients were included. While 68 % had HbA1c &lt; 8 %, only 21 % met the CGM targets (<em>P</em> &lt; 0.005). Mean glucose levels were significantly lower on dialysis days (−13 mg/dl, <em>P</em> &lt; 0.0001), without an increase in hypoglycemic episodes. Discrepancies between HbA1c and CGM metrics were associated with diabetes-related nephropathy and longer duration of HD.</div></div><div><h3>Conclusion</h3><div>HbA1c alone may substantially underestimate glycemic burden in patients on hemodialysis. CGM provides a more accurate assessment of glucose control and reveals undetected hypo- and hyperglucose levels. Incorporating CGM into routine care may improve diabetes management and therapeutic decision-making in this high-risk population.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 1","pages":"Article 101720"},"PeriodicalIF":4.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145696550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Handgrip strength cut-off points for identifying French adults at risk of type 2 diabetes","authors":"Thi Chi Phuong Nguyen ,&nbsp;Jean-Michel Oppert ,&nbsp;Laurent Bourhis ,&nbsp;Alice Bellicha ,&nbsp;Bernard Srour ,&nbsp;Emmanuelle Kesse-Guyot ,&nbsp;Serge Hercberg ,&nbsp;Pilar Galan ,&nbsp;Mathilde Touvier ,&nbsp;Léopold K Fezeu ,&nbsp;Jérémy Vanhelst","doi":"10.1016/j.diabet.2025.101713","DOIUrl":"10.1016/j.diabet.2025.101713","url":null,"abstract":"<div><h3>Aim</h3><div>To identify cut-off points for handgrip strength (HGS) detecting T2D risk among adults in France, and to examine the relationships between absolute and relative HGS and the incidence of T2D.</div></div><div><h3>Methods</h3><div>Data from 18,519 adults (5096 men) in the NutriNet-Santé cohort, were analyzed. HGS was measured using dynamometry on both hands. Nine indicators were derived, including absolute values and those relative to body weight and BMI. Receiver Operating Characteristic curves and cubic splines were used to assess predictive performance, as well as cut-off points for HGS that maximize this performance. Cox proportional hazards models were used to evaluate associations between reduced HGS and T2D.</div></div><div><h3>Results</h3><div>Over 9.8 years, 329 incident T2D cases were validated. Absolute HGS showed not associated with T2D risk, whereas higher relative HGS was associated with lower risk (e.g. HR for HGS relative to body weight: 1.30, 95 % CI: 1.07–1.58). Relative HGS showed better discrimination (AUC 0.623–0.675) than absolute HGS (≤ 0.44). Optimal cut-offs were 0.446 kg/kg and 1.086 kg/kg/m² (dominant hand), and 0.397 kg/kg and 1.033 kg/kg/m² (non-dominant). Low relative HGS was associated with increased risk (HRs 1.42–1.68), consistent across sensitivity, sex, and age analyses.</div></div><div><h3>Conclusions</h3><div>Relative, but not absolute, handgrip strength is independently associated with T2D incidence and shows modest discriminative ability. Given its simplicity and cost-effectiveness, grip strength may be a useful screening tool in clinical and public health settings.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 1","pages":"Article 101713"},"PeriodicalIF":4.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145497877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Omnipod 5 cost effective for the management of type 1 diabetes among adults in France?","authors":"Jean-Pierre Riveline ,&nbsp;Colin Hopley ,&nbsp;Anamaria-Vera Olivieri ,&nbsp;Gabriel Guigand ,&nbsp;Melanie Littlewood ,&nbsp;Alfred Penfornis","doi":"10.1016/j.diabet.2025.101721","DOIUrl":"10.1016/j.diabet.2025.101721","url":null,"abstract":"<div><h3>Aim</h3><div><em>-</em>To compare long-term cost-effectiveness between the Omnipod® 5 Automated Insulin Delivery System and continuous subcutaneous insulin infusion + continuous glucose monitoring for type 1 diabetes among adults in France.</div></div><div><h3>Methods</h3><div><em>-</em> The analysis used the IQVIA Core Diabetes Model (v9.5) and considered both the French healthcare system and societal perspective. The study population and treatment effects were from the OP5–003 randomized controlled trial. Life-years, quality-adjusted life-years, incremental cost-effectiveness ratios and incremental cost-utility ratios, modeled over a 50-year horizon (base case), were analyzed. Sensitivity analyses were conducted to test treatment effects with different time horizons and discounting. Utility values were based on Omnipod 5 EuroQoL 3-Dimensions data and literature sources.</div></div><div><h3>Results</h3><div><em>-</em> In the base case, Omnipod 5 showed better clinical outcomes and lower diabetes-related complication rates than continuous subcutaneous insulin infusion + continuous glucose monitoring, gaining 0.373 life-years and 1.568 quality-adjusted life-years (incremental cost-utility ratio considering direct costs from a healthcare perspective = €791 per quality-adjusted life-year). With Omnipod 5, although direct healthcare costs were €1240 higher, there were savings from reduced complications, and total costs including societal productivity were €3071 lower. Sensitivity analyses confirmed lower total costs with Omnipod 5 across time horizons and discounting, and the direct cost-utility ratio was €2438 per quality-adjusted life-year when the treatment effect on glycosylated hemoglobin was halved.</div></div><div><h3>Conclusion</h3><div><em>-</em> Considering the reported benefits on glycemic control and health-related quality of life, Omnipod 5 is a cost-effective alternative to continuous subcutaneous insulin infusion + continuous glucose monitoring for adults with type 1 diabetes in France.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 1","pages":"Article 101721"},"PeriodicalIF":4.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145784216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported outcome measures (PROMs) are differently associated with treatment modalities, household income, and diabetes-related events in children with type 1 diabetes, their mothers, and their fathers: a French nationwide survey","authors":"Emmanuelle Labarre ,&nbsp;Laurent Poiroux ,&nbsp;Marc De Kerdanet ,&nbsp;Line Lobel ,&nbsp;Bétina Porcel ,&nbsp;Aurélie Donzeau ,&nbsp;Carine Choleau ,&nbsp;Jacques Beltrand ,&nbsp;Regis Coutant","doi":"10.1016/j.diabet.2025.101711","DOIUrl":"10.1016/j.diabet.2025.101711","url":null,"abstract":"<div><h3>Aim</h3><div>To conduct a population-based study on the quality of life (QoL) in families (mothers, fathers, and children) of children using closed loop (CL) compared to those using multiple daily injections (MDI), open loop (OL), and low glucose suspend (LGS) systems.</div></div><div><h3>Methods</h3><div>A nationwide French survey of children with type 1 diabetes (T1D) and their parents was conducted through the national family association, <em>Familles AJD</em>, in 2024. Six validated questionnaires were used for assessing QoL, anxiety, time spent managing diabetes, and sleep quality. Multivariate analyses were performed.</div></div><div><h3>Results</h3><div>We collected 1593 surveys (1093 from mothers, 242 from fathers, and 258 from children &gt; 8 years). T1D children were aged 11.3 ± 4 years, had diabetes for 4.7 ± 3.8 years; 18% used MDI, 41% OL, 13% LGS, and 29% CL. HbA1c was 7.3 ± 0.6% with CL, vs. 7.7 ± 1.0% for other treatments (<em>P</em> &lt; 0.05). CL was associated with improved QoL scores in parents (compared to OL and MDI), and children (compared to OL, not MDI). Time spent managing diabetes was lower with CL in parents, not children. Anxiety and sleep quality were not improved with CL. Child age (in parents) and household income (in all) were associated with improved QoL. HbA1c and a history of ketoacidosis (in mothers), or a history of severe hypoglycemia (in children), had a deleterious effect. Mothers experienced lower QoL, but scores correlated within the household.</div></div><div><h3>Conclusion</h3><div>CL enhanced the QoL in families of children with T1D. Socioeconomic factors and diabetes-related events influence QoL differently depending on the respondent group.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 1","pages":"Article 101711"},"PeriodicalIF":4.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145474837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}